Peripheral Neuropathy Due to Systemic Lupus Erythematosus (SLE) Itself: Incidence, Disease Risk Factors and Outcome

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorFARGETTI, Simone
dc.contributor.authorSHINJO, Samuel K.
dc.contributor.authorPASOTO, Sandra G.
dc.contributor.authorCALICH, Ana L.
dc.contributor.authorBONFA, Eloisa
dc.contributor.authorBORBA, Eduardo F.
dc.date.accessioned2013-10-11T21:16:36Z
dc.date.available2013-10-11T21:16:36Z
dc.date.issued2012
dc.description.abstractBackground/Purpose: Peripheral neuropathy (PN) solely attributable to SLE itself is difficult to define since most of these patients are exposed to several other conditions that may cause this manifestation. The aim is to determine characteristics and outcome of PN attributed exclusively to SLE and its possible association with clinical/laboratorial features in a large cohort. Methods: SLE patients (ACR 1997) with PN were identified from our Lupus Outpatient Clinic computerized database of 1038 patients. Only patients with definitive PN proved by electroneuromyography were included. Exclusion criteria were conditions related to PN: diabetes mellitus, alcohol consumption, use of any drug related to neuropathy (thalidomide, statins, etc.), thyroid disease, infection, cancer, vitamin B12 deficiency, renal or hepatic failure, and other autoimmune disease (antiphospholipid syndrome, Sjogren’s syndrome, etc.). Medical records were extensively reviewed and included clinical/laboratorial data, treatment, and evolution. Each SLE patient with PN [n 22] was compared with 2 SLE patients without PN (controls) [n 44] that were age- and sex-matched and had similar disease duration. Results: PN exclusively attributed to SLE was identified in 22 patients (2.1%). The mean age (34.4 11.6 vs. 33.9 9.6 years, p 0.85) and disease duration (9.2 7.7 vs. 9.9 6.8 years, p 0.73) of PN were similar to controls. The interval between SLE onset and PN diagnosis was 4.9 5.7 years and the mean SLEDAI scores was higher in PN patients (5.4 7.6 vs. 1.8 2.9,p 0.001). The most common pattern on electroneuromyography was sensorimotor polyneuropathy of lower limbs (50%), followed by monon-europathy (26.9%), and polyradiculoneuropathy (15.3%). PN was associated to hematological involvement (72.7% vs. 43.2%,p 0.036), leukopenia (50% vs. 20.5%,p 0.022), lymphopenia (68.2% vs. 29.5%,p 0.004), cutaneous vasculitis (54.5% vs. 22.7%,p 0.014), and anti-Sm (50% vs. 15.9%,p 0.007). Multivariate analysis revealed that PN was related to anti-Sm (OR 5.36; 95%CI 1.37–20.99) and cutaneous vasculitis (OR 4.97; 95%CI 1.23–20.08). All SLE patients received corticosteroids, most of them associated with immunosuppressive drug (59% cyclophosphamide; 31.8% azathioprine). After immunosuppressive therapy, 63.6% improved of neurological symptoms and 31.8% remained stable. Conclusion: Our study suggested that PN attributed to SLE itself is rare in the absence of other conditions and seems to be strongly associated to anti-Sm antibodies and cutaneous vasculitis. A favorable outcome with immunosuppressive therapy is observed in most of SLE patients with this neurological manifestation.
dc.description.conferencedateNOV 09-14, 2012
dc.description.conferencelocalWashington - DC, EUA
dc.description.conferencenameAnnual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP)
dc.description.indexMEDLINE
dc.identifier.citationARTHRITIS AND RHEUMATISM, v.64, n.10, suppl.S, p.S273-S273, 2012
dc.identifier.issn0004-3591
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/2694
dc.language.isoeng
dc.publisherWILEY-BLACKWELL
dc.relation.ispartofArthritis and Rheumatism
dc.rightsrestrictedAccess
dc.rights.holderCopyright WILEY-BLACKWELL
dc.subject.wosRheumatology
dc.titlePeripheral Neuropathy Due to Systemic Lupus Erythematosus (SLE) Itself: Incidence, Disease Risk Factors and Outcome
dc.typeconferenceObject
dc.type.categorymeeting abstract
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.contributor.author-fmusphcSIMONE FARGETTI
hcfmusp.contributor.author-fmusphcSAMUEL KATSUYUKI SHINJO
hcfmusp.contributor.author-fmusphcSANDRA GOFINET PASOTO
hcfmusp.contributor.author-fmusphcANA LUISA GARCIA CALICH
hcfmusp.contributor.author-fmusphcELOISA SILVA DUTRA DE OLIVEIRA BONFA
hcfmusp.contributor.author-fmusphcEDUARDO FERREIRA BORBA NETO
hcfmusp.description.beginpageS273
hcfmusp.description.endpageS273
hcfmusp.description.issue10
hcfmusp.description.issuesuppl S
hcfmusp.description.volume64
hcfmusp.origemWOS
hcfmusp.origem.wosWOS:000309748301169
hcfmusp.publisher.cityHOBOKEN
hcfmusp.publisher.countryUSA
relation.isAuthorOfPublication863d9f70-59dc-473b-a211-7fddbdfb33f6
relation.isAuthorOfPublication07f179c5-58d8-4efe-832c-52095a9009d6
relation.isAuthorOfPublication6032e83a-1e45-4687-b844-e1ef69997c95
relation.isAuthorOfPublicationed93798d-222a-4730-8953-226b3322ae1a
relation.isAuthorOfPublication708e64de-56af-4523-b920-b237f71535b2
relation.isAuthorOfPublicationff552d3d-2962-42d9-a9f3-99f3990380fa
relation.isAuthorOfPublication.latestForDiscovery863d9f70-59dc-473b-a211-7fddbdfb33f6
Arquivos
Coleções
Comunicações em Eventos - FM/MCM
Comunicações em Eventos - HC/ICHC
Comunicações em Eventos - LIM/17